Waters Podcast # 6 : Unraveling the Analytical Complexity of Subunit Vaccines
UPLC, QTof, HDMS, and more: A practical guide to the hottest techniques driving the future of biopharmaceutical science
As firms increasingly invest in biopharmaceutical development, there is a widespread need to educate scientists in new technologies and approaches in this rapidly evolving industry. For maximum effectiveness in drug development, the application of new techniques can save time and development costs. In this podcast series, we’ll provide you with a firm knowledge of the latest technological innovations in LC and LC/MS that have been designed to address and advance the very specific needs of the many applications areas in the biopharmaceutical laboratory.Through a variety of topics highlighting our latest scientific work, this series will help you gain a better understanding of key bio-focused LC, MS, and software advancements. Learn how these solutions have been adopted by industry leaders around the world and how easy it is to implement the tools that deliver faster, better answers relating to the character and quality of your biopharmaceuticals.
In this podcast we’ll discuss how LCMS can provide important insight into developing subunit vaccines. Tasks that can be performed more efficiently include quantifying proteins in formulation, coping with formulation products, and providing a first line of analysis for these complex biotherapeutics. Modern trends towards Protein Subunit Vaccines have advantages for manufacturing and therefore warrant a careful consideration of analytical techniques that impact on business efficiency.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
